PE20010662A1 - Sal hemisulfato de 3-[n-metil-2(r)-pirrolidinilmetil]-5-(2-fenilsulfoniletil)-1h-indol - Google Patents

Sal hemisulfato de 3-[n-metil-2(r)-pirrolidinilmetil]-5-(2-fenilsulfoniletil)-1h-indol

Info

Publication number
PE20010662A1
PE20010662A1 PE2000001010A PE0010102000A PE20010662A1 PE 20010662 A1 PE20010662 A1 PE 20010662A1 PE 2000001010 A PE2000001010 A PE 2000001010A PE 0010102000 A PE0010102000 A PE 0010102000A PE 20010662 A1 PE20010662 A1 PE 20010662A1
Authority
PE
Peru
Prior art keywords
isolate
solvent
pyrrolidinylmethyl
indole
methyl
Prior art date
Application number
PE2000001010A
Other languages
English (en)
Inventor
Ronald James Ogilvie
Arthur Bentley
Simon Arnold Howard-Field
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20010662A1 publication Critical patent/PE20010662A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UNA SAL POLIMORFICA CRISTALINA DEL 3-[N-METIL-2(R)-PIRROLIDINILMETIL]-5-(2-FENILSULFONILETIL)-1H-INDOL DE FORMULA I (ELETRIPTAN) CARACTERIZADA POR EL PATRON DE DIFRACCION DE RAYOS X, ESPECTRO INFRARROJO, EL VALOR DE CALORIMETRIA DIFERENCIAL A 226°C. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE DISOLVER UN COMPUESTO DE FORMULA II EN UN DISOLVENTE COMO ACETONA, TETRAHIDROFURANO; CON ACIDO SULFURICO CONCENTRADO; CALENTAR BAJO REFLUJO EN EL PRIMER DISOLVENTE, ENFRIAR, AISLAR LA FORMA POLIMORFICA DESEADA, AISLAR LA SUSPENSION RESULTANTE, RECOGERLA EN UN SEGUNDO DISOLVENTE TAL COMO ACETONA, TETRAHIDROFURANO, ETANOL, ISOPROPANOL; CALENTAR BAJO REFLUJO; ENFRIAR; AISLAR LA FORMA POLIMORFICA DESEADA. EL COMPUESTO ES UN AGONISTA DEL RECEPTOR DE SEROTONINA 5HT-1 Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA MIGRANA, CEFALEA EN RACIMOS, HEMICRANEA PAROXISTICA CRONICA, CEFALEA ASOCIADA A UN TRASTORNO VASCULAR, DEPRESION, ANSIEDAD, OBESIDAD, ABUSO DE FARMACOS, HIPERTENSION, EMESIS
PE2000001010A 1999-09-28 2000-09-26 Sal hemisulfato de 3-[n-metil-2(r)-pirrolidinilmetil]-5-(2-fenilsulfoniletil)-1h-indol PE20010662A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9922963.5A GB9922963D0 (en) 1999-09-28 1999-09-28 Polymorphic salt

Publications (1)

Publication Number Publication Date
PE20010662A1 true PE20010662A1 (es) 2001-06-23

Family

ID=10861767

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001010A PE20010662A1 (es) 1999-09-28 2000-09-26 Sal hemisulfato de 3-[n-metil-2(r)-pirrolidinilmetil]-5-(2-fenilsulfoniletil)-1h-indol

Country Status (50)

Country Link
US (1) US6369094B1 (es)
EP (1) EP1233960B1 (es)
JP (1) JP3795395B2 (es)
KR (1) KR100479897B1 (es)
CN (1) CN1155594C (es)
AP (1) AP2004A (es)
AR (1) AR025779A1 (es)
AT (1) ATE246185T1 (es)
AU (1) AU779580B2 (es)
BG (1) BG65161B1 (es)
BR (1) BR0014272A (es)
CA (1) CA2379572C (es)
CO (1) CO5180567A1 (es)
CR (1) CR6561A (es)
CU (1) CU23200A3 (es)
CZ (1) CZ2002971A3 (es)
DE (1) DE60004262T2 (es)
DK (1) DK1233960T3 (es)
DZ (1) DZ3254A1 (es)
EA (1) EA004510B1 (es)
EE (1) EE200200171A (es)
EG (1) EG24143A (es)
ES (1) ES2200911T3 (es)
GB (1) GB9922963D0 (es)
GE (1) GEP20043365B (es)
GT (1) GT200000159A (es)
HK (1) HK1048628B (es)
HR (1) HRP20020270B1 (es)
HU (1) HUP0202821A3 (es)
IL (1) IL147154A (es)
IS (1) IS2162B (es)
MA (1) MA26821A1 (es)
MX (1) MXPA02003311A (es)
MY (1) MY121170A (es)
NO (1) NO321936B1 (es)
NZ (1) NZ516093A (es)
OA (1) OA12024A (es)
PA (1) PA8498901A1 (es)
PE (1) PE20010662A1 (es)
PL (1) PL354960A1 (es)
PT (1) PT1233960E (es)
SI (1) SI1233960T1 (es)
SK (1) SK3982002A3 (es)
TN (1) TNSN00187A1 (es)
TR (1) TR200200804T2 (es)
TW (1) TWI265926B (es)
UA (1) UA72272C2 (es)
WO (1) WO2001023377A2 (es)
YU (1) YU2602A (es)
ZA (1) ZA200202406B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US20060025387A1 (en) * 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
CA2588465C (en) * 2004-12-03 2013-10-01 Merck & Co., Inc. Pharmaceutical composition containing an anti-nucleating agent
JP2009511629A (ja) * 2005-10-17 2009-03-19 ニューロセラピューティクス ファーマ， インコーポレイテッド 中枢神経系疾患の調節に有用な利尿薬様化合物類似体
KR100814109B1 (ko) * 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
TWI394753B (zh) * 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
PL2493312T3 (pl) 2009-10-26 2022-01-03 Merck Sharp & Dohme Corp. Kompozycje farmaceutyczne w postaci ciała stałego zawierające inhibitor integrazy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5559246A (en) 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
RO111767B1 (ro) * 1990-10-15 1997-01-30 Pfizer Derivati de indol, procedee si intermediari pentru prepararea acestora, compozitii farmaceutice si metoda pentru tratarea unor afectiuni
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
US6166025A (en) * 1997-07-03 2000-12-26 Pfizer Inc. Pharmaceutical compositions containing eletriptran hemisulphate and caffeine

Also Published As

Publication number Publication date
CO5180567A1 (es) 2002-07-30
TNSN00187A1 (fr) 2005-11-10
HK1048628B (zh) 2004-10-21
WO2001023377A3 (en) 2002-03-07
GT200000159A (es) 2002-03-20
GB9922963D0 (en) 1999-12-01
KR20020032627A (ko) 2002-05-03
TWI265926B (en) 2006-11-11
ZA200202406B (en) 2003-05-28
CR6561A (es) 2005-04-04
HUP0202821A2 (hu) 2003-01-28
EP1233960B1 (en) 2003-07-30
WO2001023377A2 (en) 2001-04-05
EA200200302A1 (ru) 2002-10-31
SI1233960T1 (en) 2003-12-31
JP2003510318A (ja) 2003-03-18
AP2002002457A0 (en) 2002-06-30
IL147154A0 (en) 2002-08-14
IS6223A (is) 2002-01-08
AU6721300A (en) 2001-04-30
AU779580B2 (en) 2005-01-27
AR025779A1 (es) 2002-12-11
EE200200171A (et) 2003-06-16
DZ3254A1 (fr) 2001-04-05
PT1233960E (pt) 2003-11-28
GEP20043365B (en) 2004-05-10
EG24143A (en) 2008-08-06
DE60004262T2 (de) 2004-01-22
MA26821A1 (fr) 2004-12-20
PA8498901A1 (es) 2004-02-07
TR200200804T2 (tr) 2002-07-22
DE60004262D1 (de) 2003-09-04
KR100479897B1 (ko) 2005-03-31
JP3795395B2 (ja) 2006-07-12
HRP20020270B1 (en) 2004-04-30
CU23200A3 (es) 2007-04-06
CA2379572C (en) 2006-11-14
NO20021525D0 (no) 2002-03-26
SK3982002A3 (en) 2003-05-02
NZ516093A (en) 2005-01-28
MXPA02003311A (es) 2002-10-04
ATE246185T1 (de) 2003-08-15
YU2602A (sh) 2004-11-25
OA12024A (en) 2006-04-19
DK1233960T3 (da) 2003-10-27
AP2004A (en) 2009-06-10
NO20021525L (no) 2002-03-26
IL147154A (en) 2005-11-20
EA004510B1 (ru) 2004-04-29
IS2162B (is) 2006-11-15
US6369094B1 (en) 2002-04-09
UA72272C2 (uk) 2005-02-15
BR0014272A (pt) 2002-05-21
HUP0202821A3 (en) 2003-12-29
CA2379572A1 (en) 2001-04-05
PL354960A1 (en) 2004-03-22
CN1364166A (zh) 2002-08-14
ES2200911T3 (es) 2004-03-16
BG106240A (en) 2002-07-31
WO2001023377A9 (en) 2002-03-28
MY121170A (en) 2005-12-30
NO321936B1 (no) 2006-07-24
EP1233960A2 (en) 2002-08-28
HRP20020270A2 (en) 2003-06-30
BG65161B1 (bg) 2007-04-30
CN1155594C (zh) 2004-06-30
CZ2002971A3 (cs) 2003-04-16
HK1048628A1 (en) 2003-04-11

Similar Documents

Publication Publication Date Title
PE20010662A1 (es) Sal hemisulfato de 3-[n-metil-2(r)-pirrolidinilmetil]-5-(2-fenilsulfoniletil)-1h-indol
US6214844B1 (en) Substituted imidazole compounds
US5739143A (en) Imidazole compounds and compositions
US6730683B2 (en) Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
AU705207B2 (en) Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine
US5864036A (en) Substituted imidazole compounds
CA2586179A1 (en) Sulfonyl benzimidazole derivatives
CA2043709C (en) Antimigraine alkoxypyrimidine derivatives
US20030069243A1 (en) Novel substituted imidazole compounds
PT98168B (pt) Processo para a preparacao de novos derivados do indole e de composicoes farmaceuticas que os contem
EP0831830A1 (en) Imidazole compounds
PE20081454A1 (es) Derivados de pirazol como moduladores del receptor 5-ht2a de serotonina utiles para el tratamiento de los transtornos relacionados con dicho receptor
KR20080021596A (ko) Ｎｏｓ 저해 활성을 갖는 치환된 인돌 화합물
CA2332402A1 (en) Novel 2-alkyl substituted imidazole compounds
EP1014976A1 (en) Novel substituted imidazole compounds
JP2013515047A (ja) プロテインキナーゼ阻害活性を有する４−フェニルアミノ−ピリミジン誘導体
EP0464604A2 (en) 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines
US20080114010A1 (en) Novel Substituted Imidazole Compounds
JP2016513128A5 (es)
EP1896449A1 (en) Heterocyclylaminoalkyl substituted benzimidazoles
US6489325B1 (en) Substituted imidazole compounds
JP2007537229A5 (es)
DE60102461T2 (de) Pyrimidinyl methyl indolderivate mit antibakterieller wirkung
JPH07504192A (ja) ５−ｈｔ３受容体拮抗剤としての２，６‐メタノ‐２ｈ‐キノリジン誘導体
AU699646C (en) Imidazole compounds

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed